An interventional study of FreeStyle Libre 3 Plus Continuous Glucose Monitor in Continuous Glucose Monitoring, Type 1 Diabetes and Type 2 Diabetes, sponsored by University of the Pacific. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by University of the Pacific · Not applicable, Interventional, and Other
This is a clinical trial looking at differences in continuous glucose monitor (CGM) glucose readings between the left and right arms in adults with type 1 or type 2 diabetes. The study will enroll 60 participants who will wear a CGM sensor on both arms for 14 days.
This study is a prospective, non-randomized clinical trial designed to evaluate differences in continuous glucose monitor (CGM) glucose readings between the left and right arms in adults with type 1 or type 2 diabetes.
The study will enroll 60 participants. Each participant will wear two FreeStyle Libre 3 Plus CGM sensors simultaneously for 14 days, with one sensor placed on each arm.
The primary objective is to compare the frequency of hypoglycemic events, defined as glucose readings below 70 mg/dL, between the left and right arms. Secondary analyses will evaluate differences in Level 1 and Level 2 hypoglycemia and time below range. Additional analyses will compare time in range, time above range, time below range, and average glucose between the two arms.
CGM data from the two sensors will be collected and compared to evaluate differences in glucose readings between the left and right arms.
3,619 studies on the registry are indexed under Diabetes Mellitus, Type 1; 587 are open to participants now.
This study's planned enrollment of 60 is above the median of 40 across 2,721 interventional studies indexed under Diabetes Mellitus, Type 1.
Browse Diabetes Mellitus, Type 1 studies →University of the Pacific is the lead sponsor of 17 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will wear two FreeStyle Libre 3 Plus continuous glucose monitors (CGMs) simultaneously for 14 days, with one sensor applied to the back of the upper arm on each arm. Participants will continue their normal daily routine during the study period. CGM data from the left and right arms will be compared.
Device: FreeStyle Libre 3 Plus Continuous Glucose Monitor
Two FreeStyle Libre 3 Plus continuous glucose monitors (CGMs) will be worn simultaneously for 14 days. One sensor will be applied subcutaneously to the back of the upper arm on each arm. The sensors measure glucose in the interstitial fluid, and data from the left and right arms will be collected and compared.
Difference in Frequency of Hypoglycemic Events Between Left and Right Arms
Difference in the frequency of hypoglycemic events (\<70 mg/dL) between the left arm and right arm.
Time frame: 14 days
Difference in Frequency of Level 1 Hypoglycemic Events Between Left and Right Arms
Difference in the frequency of Level 1 hypoglycemic events (54 to \<70 mg/dL) between the left arm and right arm.
Time frame: 14 days
Difference in Frequency of Level 2 Hypoglycemic Events Between Left and Right Arms
Difference in the frequency of Level 2 hypoglycemic events (\<54 mg/dL) between the left arm and right arm.
Time frame: 14 days
Difference in Percentage of Time Below Range (<70 mg/dL) Between Left and Right Arms
Difference in percentage of time below range (TBR) \<70 mg/dL between the left and right arms.
Time frame: 14 days
Difference in Percentage of Time Below Range (54 to <70 mg/dL) Between Left and Right Arms
Difference in percentage of time below range (TBR) from 54 to \<70 mg/dL (Level 1 hypoglycemia) between the left and right arms.
Time frame: 14 days
Difference in Percentage of Time Below Range (<54 mg/dL) Between Left and Right Arms
Difference in percentage of time below range (TBR) \<54 mg/dL (Level 2 hypoglycemia) between the left and right arms.
Time frame: 14 days
Plan to share: No — Individual participant data will not be shared with others.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.
Of 822 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 37. This study's planned 12 months is below that.
Counting every sponsor, half of 922 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of the Pacific